Madhavan Balachandran Increases Stake in uniQure N.V.
Madhavan Balachandran purchased 11,685 shares of uniQure N.V. on June 17, 2026.
Key Points
- Madhavan Balachandran bought 11,685 shares of uniQure N.V. at an average price of $24.97, totaling $291,806 on June 17, 2026.
- uniQure N.V. trades on NasdaqGS under the ticker QURE, with a market cap of $2.92 billion and a 52-week range of $8.73 to $71.50.
- Analyst firms like Barclays upgraded uniQure to a 'buy' with a $65 target, while Goldman Sachs maintained a 'hold' rating with a $46 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Madhavan Balachandran recently increased his stake in uniQure N.V. (NasdaqGS: QURE) by purchasing 11,685 shares. The transaction, completed on June 17, 2026, was valued at approximately $291,806, with an average share price of $24.97.
Insider Buying and Selling at uniQure N.V.
Madhavan Balachandran's recent purchase was not under a pre-planned trading program. On the same day, CEO Matthew Kapusta also engaged in trading activities, selling 41,671 shares at $50 each as part of a planned sale, and buying 4,656 shares at $31.71.
Other Institutional Activity in uniQure N.V.
Several institutional investors have also been active in uniQure. Avoro Capital Advisors LLC reduced its holdings by 190,405 shares, ending with 5,959,595 shares valued at about $97.4 million, a 3.1% decrease. Aberdeen Group PLC, on the other hand, increased its position by 1,627,746 shares, holding 5,306,386 shares worth approximately $86.8 million, marking a 44.2% increase. Two Sigma Investments, LP significantly boosted its stake by 1,224,587 shares, now holding 2,675,871 shares valued at $43.8 million, an 84.4% increase.
uniQure N.V. Stock Down 6.1%
Shares of uniQure N.V. traded near $46.37 on Monday. The company, with a market capitalization of approximately $2.92 billion, has a 52-week low of $8.73 and a high of $71.50. The stock's 50-day moving average is $24.13, while the 200-day moving average is $27.53. The firm maintains a high current ratio of 10.40 and a quick ratio of 9.97, though it carries a debt-to-equity ratio of 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 18, 2026, Barclays upgraded uniQure to a "buy" rating with a price target of $65. Goldman Sachs maintained a "hold" rating with a $46 target. Similarly, Leerink Partners and RBC Capital both reaffirmed their "buy" ratings, setting targets at $70 and $65, respectively. The stock has a consensus "strong buy" recommendation with an average target price of $58.75, based on 11 analyst opinions.
About uniQure N.V.
uniQure N.V. is a biotechnology company headquartered in Amsterdam, Netherlands. It focuses on developing gene therapies for rare and serious diseases. Its key product is HEMGENIX for hemophilia B, and its lead candidate AMT-130 is in clinical trials for Huntington's disease. The company also has a pipeline targeting epilepsy, ALS, and Fabry disease. Founded in 1998, uniQure operates in the healthcare sector with a workforce of 221 employees.
Bottom Line
Madhavan Balachandran's recent purchase of uniQure shares is noteworthy amid other institutional activities. While insider transactions like these can offer insights, they don't necessarily predict future stock performance. Investors should consider uniQure's broader market context, including its clinical pipeline and financial metrics, when evaluating its potential.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.